{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "XNCR",
  "name": "Xencor, Inc.",
  "url": "https://orbyd.app/dossiers/XNCR/",
  "json_url": "https://orbyd.app/dossiers/XNCR.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Royalty-collector-to-owned-pipeline pivot; XmAb819 ccRCC data at ESMO (Oct 23–27) is the real binary but ~90 days out. Stock ran $6.92→$17.47 to near 52-week highs on pipeline optimism while royalty revenue collapses (Q1 $4.5M vs $32.7M YoY). Extended, no 30-day catalyst — stand aside for a base.",
  "invalidation_trigger": "A weekly close below $14 loses the early-July breakout shelf and the higher-low structure off the $6.92 low, ending the momentum leg; an XmAb819 ESMO data slip past October or an Ultomiris dispute resolved against Xencor breaks it independently.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 print est. ~2026-08-06 — treat the ~3 trading days prior as an earnings blackout for fresh entries.",
    "The real binary is XmAb819 ccRCC expansion-cohort data at ESMO 2026-10-23 to 10-27 (~90 days out); no dated catalyst before then.",
    "Ultomiris royalty dispute with AstraZeneca/Alexion is an unresolved revenue overhang that ties value to a legal outcome.",
    "July 20 gainers-list pop was a retail-flow screen (grouped with crypto miners IREN/HUT/CIFR/CLSK/APLD and AMC), not oncology-cluster confirmation.",
    "Cash $541.8M at 3/31/26, guided $380–400M by YE2026, runway into mid-2028; burn ~$150M/yr keeps a dilution clock running."
  ],
  "body_markdown": "## Current Thesis\nXencor is mid-transition from a royalty collector into a wholly-owned-pipeline biotech, and that pivot is what buyers are re-rating. Royalty revenue is collapsing (Q1 2026 revenue $4.5M vs $32.7M a year earlier, reported May 6, 2026) as Ultomiris royalties shrink and a royalty dispute with AstraZeneca/Alexion sits unresolved. In its place the story is XmAb819 (ENPP3 × CD3 bispecific) in clear-cell renal cell carcinoma and XmAb942 (TL1A) in ulcerative colitis. The stock ran from a $6.92 52-week low to a $17.47 close (July 17, 2026, +16.9%) on pipeline optimism, not a data print — and the actual binary, XmAb819 expansion-cohort data, does not land until ESMO on October 23–27, roughly a quarter away. That leaves a name extended near 52-week highs with no catalyst inside 30 days and a Q2 report due in early August. The clean structure is a base or a pullback-to-support reclaim, not a chase into highs.\n\n## Bull Case\n- **First late-stage owned asset getting a stage:** XmAb819 (ENPP3 × CD3) expansion-cohort data in advanced ccRCC was accepted for oral presentation at ESMO, October 23–27, 2026 (announced July 17). Management frames it as support for a first pivotal study planned in 2027 — the concrete step the pivot narrative needs.\n- **TL1A optionality:** XmAb942 is enrolling the global Phase 2b XENITH-UC study in ulcerative colitis. TL1A is a sought-after IBD mechanism — Merck paid ~$10.8B for Prometheus (2023) and Roche ~$7.1B for Televant (2023) — so a credible Phase 2b readout carries partnering/M&A optionality.\n- **Funded through the readouts:** $541.8M in cash and marketable securities at March 31, 2026, guided to $380–400M by year-end, runway into mid-2028 (May 6). The pipeline can reach data without a near-term raise.\n- **Momentum structure intact:** +16.9% to $17.47 on July 17 off a $6.92 52-week low, trading in the top decile of its range near the $18.69 high.\n- **Sell-side still constructive:** Truist maintained Buy on July 7, 2026, with a $27 target — roughly 55% above the July 17 close even after the cut.\n\n## Bear Case\n- **The revenue engine is failing:** Q1 2026 revenue $4.5M vs $32.7M YoY; the Incyte milestone did not repeat and Ultomiris royalties were reduced. An active Ultomiris royalty dispute with AstraZeneca/Alexion ties a chunk of value to a legal outcome.\n- **Heavy burn, dilution clock running:** Q1 net loss $128.9M / EPS -$1.71 (includes a Zenas write-down). Cash guided down ~$150M this year; a raise becomes a live question well before mid-2028.\n- **No 30-day fuel:** The real driver (XmAb819 data) is ~90 days out. The July 20 \"moving higher\" appearance was a retail gainers screen alongside crypto miners (IREN, HUT, CIFR, CLSK, APLD) and AMC — flow, not oncology-cluster confirmation.\n- **Target direction is down:** Truist cut its PT to $27 on July 7 even while keeping Buy; estimate revisions are lower.\n- **Early, binary science:** XmAb819 is a Phase 1 asset, and single-arm bispecific T-cell-engager data in solid tumors has a long record of CRS and efficacy disappointments. This is an unproven readout, not a de-risked one.\n\n## Setup & Price Structure\n- Last reference ~$17.47 (July 17 close); 52-week range $6.92–$18.69, so price is pressed against the upper boundary near highs.\n- Pre-pop consolidation shelf sat roughly $14.69–$15.72 in early July; the July 17 session gapped +16.9% through it on volume.\n- The trend off the spring lows is up and the 20-week structure is rising, but the momentum leg has no near-term catalyst behind it — a MATURING advance running ahead of its data, rather than an accelerating one with a scheduled binary.\n- For a fresh entry the risk/reward is poor: extended ~150% off the low, into a Q2 print, with the value-inflection event a quarter away. A reclaim of the early-July shelf as support after a pullback is the cleaner structure to buy.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-10-23 to 2026-10-27 (beyond 30d, the real driver):** XmAb819 ccRCC expansion-cohort data, oral presentation at ESMO.\n- **H2 2026 – 2027:** XmAb942 XENITH-UC (ulcerative colitis) enrollment/interim progress — no fixed date.\n- **2027 (planned):** initiation of the first XmAb819 pivotal study.\n\n## Elapsed catalysts\n\n- **~2026-08-06 (est.):** Q2 2026 financial results — royalty trajectory, Ultomiris-dispute status, updated cash burn. Binary enough to warrant standing aside into the print rather than entering ahead of it. *(passed 3d ago)*\n\n## What Would Change Our Mind\n- **Bull confirmation:** a decisive reclaim and hold above the $18.69 52-week high on expanding volume with oncology-immunology peers participating would flip the read to a re-accelerating theme and justify a momentum entry. A positive XmAb819 data pre-signal or a TL1A partnering headline would do the same.\n- **Invalidation:** a weekly close below $14 loses the early-July breakout shelf and the higher-low structure built off the $6.92 low, ending the momentum leg. A resolution of the Ultomiris dispute against Xencor, or XmAb819 data slipping past ESMO, would independently break the thesis.\n\n## Correlation Notes\n- Clinical-stage antibody biotech: moves with XBI biotech beta and small-cap risk appetite far more than any AI/semis theme; rate-sensitive on the funding side.\n- TL1A read-through peers: Merck (post-Prometheus), Roche (Televant), plus Teva/Sanofi duvakitug — XmAb942 enters a crowded IBD field where competitive data can reprice it.\n- Royalty read-through: Ultomiris (AstraZeneca/Alexion) and Monjuvi/tafasitamab (Incyte) — both declining, and the Ultomiris leg is now a legal-outcome variable.\n- The July 20 gainers grouping was a retail-flow screen (crypto miners and AMC), so that day's move should be treated as noise rather than fundamental confirmation.",
  "first_seen": "2026-07-20",
  "last_analyzed": "2026-08-09T08:10:09+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}